Ask about this productRelated genes to: PRMT8 antibody
- Gene:
- PRMT8 NIH gene
- Name:
- protein arginine methyltransferase 8
- Previous symbol:
- HRMT1L3, HRMT1L4
- Synonyms:
- -
- Chromosome:
- 12p13.32
- Locus Type:
- gene with protein product
- Date approved:
- 2000-08-01
- Date modifiied:
- 2016-10-05
Related products to: PRMT8 antibody
Related articles to: PRMT8 antibody
- Alzheimer's disease (AD) is characterized by progressive neurodegeneration driven by tau and amyloid-β (Aβ) pathology, although the underlying molecular mechanisms remain incompletely understood. Emerging evidence implicates altered DNA methylation (DNAm) in AD but comprehensive analyses in experimental models are limited. Here, we profile DNAm dynamics in two widely used transgenic mouse models of tau (rTg4510) and Aβ (J20) neuropathology, focusing on the entorhinal cortex and hippocampus. Using reduced representation bisulfite sequencing (RRBS) and methylation arrays across multiple disease stages, we identified widespread pathology-associated DNAm alterations in both models. Tau pathology in rTg4510 mice was associated with extensive DNAm remodeling at genes involved in neuronal plasticity, apoptosis, and lipid metabolism, including , , and . In contrast, J20 mice exhibited more modest changes, primarily at immune-related loci such as , , and . Tau-associated DNAm changes were more consistent across brain areas than those associated with Aβ pathology. Comparison with human AD DNAm datasets revealed overlapping DNAm differences, including hypermethylation at and in rTg4510 mice. These findings provide robust evidence for early, pathology-associated epigenetic alterations in AD and highlight the utility of epigenomic profiling in transgenic models for identifying novel targets for early intervention in AD. - Source: PubMed
Publication date: 2026/04/07
Leung Szi KayWalker Emma MPolicicchio StefaniaDahir AishaVellame Dorothea SeilerSmith Adam RSwarbrick RhianLunnon KatieDempster Emma LAhmed ZeshanHannon EilisCastanho IsabelMill Jonathan - In recent decades, genetic research in cattle has largely prioritised cosmopolitan breeds and production traits, often overlooking functional and fitness-related characteristics such as longevity, fertility, and udder health. These fitness traits, although critical for animal welfare and sustainable farming, are challenging to improve due to their low heritability and complex genetic background. This study investigates the genomic architecture of three key fitness traits: longevity (LONG), fertility (measured as days open, DO), and udder health (somatic cell score, SCS)-in two local dual-purpose breeds, Alpine Grey (AG) and Rendena (RE), using a genome-wide association study (GWAS). For AG breed, 2 745 genotyped animals were considered and 2 251 from the RE breed. For LONG, 37 053 and 9 782 phenotypic records were, in AG and RE, respectively, while 30 316 (AG) and 19 822 (RE) for DO; and 113 297 (RE) and 792 921 (AG) for both SCS and milk yield. In GWAS, pseudophenotypes were utilised to address data imbalance. A total of 744 quantitative trait loci (QTLs) associated with the three traits were identified, which were associated with 26 annotated genes explaining more than 1% of the additive genetic variance. Candidate genes significantly associated with target traits include CPEB4 (LONG in RE, SCS in both breeds), DSC2 (DO in AG, SCS in RE), LCORL (LONG and SCS in RE), PRMT8 (LONG in both breeds, MY in RE), RAPGEF6 (LONG in AG), TEAD4 (MY in RE), TSPAN9 (LONG in both), and XKR4 (DO and SCS in RE). These genes participate in vital biological functions such as spermatogenesis, mitochondrial regulation, cellular signalling, and tissue integrity, underlining their relevance in fertility, animal health, and productivity. Notably, several genes identified as significant in our study have previously been associated with both milk and beef production traits in the literature, suggesting that key functional traits related to dual-purpose performance remain detectable despite ongoing selection primarily focused on milk yield. This versatility is essential for their continued adaptability to diverse farming systems and market needs. Overall, the findings provide insights into genomic regions associated with fitness traits in local cattle breeds, emphasizing the value of integrating these traits into breeding programmes. The identification of genetic markers offers valuable opportunities to improve selection strategies that promote animal welfare and sustainable production, reinforcing the role of genetic diversity in dual-purpose local breeds within modern agriculture. - Source: PubMed
Publication date: 2026/02/20
Oian AMancin EGomez Proto GRulli ESartori CMantovani R - Beyond follicular-derived thyroid carcinomas, lymphomas, and metastatic disease, there are rare pathologies of the thyroid gland that represent a challenge. We report patients with unusual malignancies that mimic similar aggressive cancers. - Source: PubMed
Publication date: 2026/03/15
Allen David ZHosseini S MohsenZafereo MarkLango MiriamGrubbs Elizabeth GardnerIyer PriyankaPatel Shreyaskumar RRavi VinodBusaidy Naifa LamkiWang Rui JenniferWilliams Michelle DCabanillas Maria EManiakas Anastasios - Triple-negative breast cancer (TNBC) remains the most refractory breast cancer subtype because of its high invasiveness, lack of therapeutic targets and heterogeneity. Type I protein arginine methyltransferases (PRMTs) are important epigenetic enzymes that catalyze the methylation of arginine residues in various proteins, playing crucial roles in numerous cellular processes. Targeting type I PRMTs represents a promising strategy for TNBC. In this study we characterized a novel selective type I PRMTs inhibitor, SKLB06489. Compared with the precursor compound SKLB06329 (F = 0.2%), SKLB06489 exhibited a markedly enhanced oral bioavailability (F = 88.4%). SKLB06489 inhibited PRMT1, PRMT6, and PRMT8 with IC values of 64.55, 4.21, and 51.27 nM, respectively. In TNBC cell lines MDA-MB-231, Hs578T, and BT549, SKLB06489 dose-dependently inhibited cell proliferation and colony formation with IC values in the low micromolar range. In MDA-MB-231 subcutaneous xenograft models, administration of SKLB06489 (40, 80 mg·kg·d, i.g. for 33 days) dose-dependently suppressed tumor growth. RNA sequencing and in vitro validation revealed that SKLB06489 inhibited TNBC proliferation by impairing DNA replication, compromising DNA damage repair, and ultimately inducing G/G-phase cell cycle arrest and apoptosis. In addition, SKLB06489 (5, 10 μΜ) dose-dependently enhanced intracellular cholesterol efflux in MDA-MB-231 cells and Hs578T cells via upregulation of the ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1), thereby disrupting cholesterol metabolic homeostasis. We conclude that SKLB06489 is a potent type Ⅰ PRMTs inhibitor with great therapeutic potential and is expected to overcome the TNBC treatment bottleneck. The discovery of SKLB06489-regulated cholesterol homeostasis provides a novel perspective on the biological function of type Ⅰ PRMTs, particularly their role in regulating metabolic pathway. - Source: PubMed
Publication date: 2026/01/16
Zhou Shu-YanZhang Qiang-ShengLi LuLiu Zhi-HaoHu XiangChen Xue-YingLi XiaoFeng Zhan-ZhanWan Guo-QuanYu Luo-Ting - Kidney function decline is associated with cardiovascular disease and various other morbidities. Previous studies regarding polygenic risk scores of estimated glomerular filtration rate (eGFR) change were generally based on individuals of European ancestry and not validated on populations of East Asian ancestry. - Source: PubMed
Publication date: 2025/09/04
Chuang Gwo-TsannHsiung Chia-NiChe Tony Pan-HouOh Kook-HwanPark Sue KMoon SungjiLee SangjunRobinson-Cohen CassianneHung Adriana MLi Wen-YiChang Yi-Cheng